Skip to main content
Evidence Snapshot

KU812 cell line

CHEMBL613997 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613997
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats KU812 cell line as ChEMBL target CHEMBL613997. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
KU812 cell line
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL613997
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why KU812 cell line matters

As of 2026-09-13

KU812 cell line is reviewed as KU812 cell line; the current evidence base includes 32 approved drugs, 178 compounds, and 57 assays, with lead potency reaching pChEMBL 10.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 32 approved drugs, 178 compounds, and 57 assays for this target. The dominant activity type is IC50. CHEMBL5416410 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL5416410 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
32 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why KU812 cell line matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

178
Total Compounds
57
Total Assays
32
Approved Drugs
IC50: 157.0, EC50: 13.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5416410
10.0 IC50 Approved
No preferred name
CHEMBL5093894
10.0 IC50
No preferred name
CHEMBL1171837
10.0 IC50 Approved
No preferred name
CHEMBL5089813
9.7 IC50
No preferred name
CHEMBL5089020
9.7 IC50

Approved Drugs

Structure Compound First Approval
SELUMETINIB
CHEMBL1614701
2020
AFATINIB
CHEMBL1173655
2013
PONATINIB
CHEMBL1171837
2012
BOSUTINIB
CHEMBL288441
2012
AXITINIB
CHEMBL1289926
2012
NILOTINIB
CHEMBL255863
2007
DASATINIB
CHEMBL5416410
2006
VORINOSTAT
CHEMBL98
2006
IMATINIB
CHEMBL941
2001
2001
SIROLIMUS
CHEMBL413
1999
GEMCITABINE
CHEMBL888
1996
DOCETAXEL
CHEMBL3545252
1995
VINORELBINE
CHEMBL553025
1994
PACLITAXEL
CHEMBL428647
1992
MITOMYCIN
CHEMBL105
1981
DOXORUBICIN
CHEMBL53463
1974
TRETINOIN
CHEMBL38
1971
VINBLASTINE
CHEMBL159
1965
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613997